Navigating new frontiers: Ways to find space in the future RA market
JAK inhibitor, RA, Research Partnership, Rheumatoid arthritis
0 Comment
RA
More good news for AbbVie in rheumatoid arthritis
AbbVie, immunology, JAK1, RA, Rheumatoid arthritis, Upadacitinib
0 Comment
AbbVie has reported positive top-line results for its oral JAK1-selective inhibitor in rheumatoid arthritis (RA), bringing it closer to a potential new early treatment option for patients.